In this randomised, controlled, open-label, platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19.

In this trial, nonhospitalized patients with symptomatic COVID-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression received a single infusion of sotrovimab at a dose of 500 mg or placebo.

The EAN Education Committee is happy to announce and introduce the recipients of the 2022 Student Teaser Fellowship. Congratulations to the winners!

In this study the authors used data on confirmed infection and severe disease collected from an Israeli national database for the period of July 11 to 31, 2021, for all Israeli residents who had been fully vaccinated before June 2021.

Safe, effective vaccines against coronavirus disease 2019 (COVID-19) are urgently needed in children younger than 12 years of age. In this article the authors present results for 5-to-11-year-old children.

The objective of this double-blind randomised controlled trial was to compare propranolol and topiramate in terms of tolerability and efficacy in preventing chronic migraine over 24 weeks.

This randomized, double-blind, placebo-controlled phase 2 clinical trial investigated the potential therapeutic value of losartan, an angiotensin II receptor antagonist, in reducing whole brain volume atrophy in patients with mild-to moderate Alzheimer’s disease.

Registration is now open for the OneNeurology European Summit, taking place virtually on Friday, 17 December.

With so few chances for EAN staff and members to meet in person, we decided to introduce the team behind the scenes. This time it's Florian, our Congress Manager, and Helene, from the Education Department.

The EAN Spring School is available to 120 clinical neurologists in training who have not yet completed their residency or clinical speciality training.

The EAN Education Committee has received numerous applications for the 2022 Research Fellowship and we are happy to announce and introduce the recipients below.

EAN President, Claudio Bassetti gives some deep insights into the EAN's recent advocacy activity and plans for the future.

Our research paper of the month is an open-label, single-arm, phase II futility trial exploring the safety and the effect of treatment with the antimalarial drug hydroxychloroquine on disability worsening in patients with primary progressive multiple sclerosis.

Our authors of the month conducted a randomised, placebo-controlled, observer-blinded, multinational study to assess the safety, efficacy and immunogenicity of the BNT162b2 vaccine.

The Austrian Society of Neurology (ÖGN - Österreichische Gesellschaft für Neurologie) will hold its 19th annual meeting in March 2022 as a physical event in Graz, Austria.